YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation

Anne Roslind; Julia S Johansen

doi:10.1007/978-1-59745-447-6_7

YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation

45 Citations (Scopus)

Abstract

YKL-40, a member of 'mammalian chitinase-like proteins', is secreted by macrophages, neutrophils, chondrocytes, endothelial-, vascular smooth muscle-, and cancer cells. High serum YKL-40 is a biomarker of poor prognosis in patients with cancer, inflammation and increased tissue remodelling. High YKL-40 protein expression assessed by immunohistochemistry is found in breast carcinomas associated with short disease-free survival and in glioblastomas with increased resistance to radiotherapy and decreased overall survival. In this chapter we describe the methods for the detection of (1) YKL-40 protein expression in human tissues (using immunohistochemistry) and cell cultures (using immunocytochemistry); (2) YKL-40 mRNA expression in human tissues (using in situ hybridization and Polymerase Chain Reaction); and (3) YKL-40 protein concentrations in serum or plasma (using Enzyme-Linked ImmunoSorbent Assay).

Original language	English
Journal	Methods in Molecular Biology
Volume	511
Pages (from-to)	159-84
Number of pages	26
ISSN	1064-3745
DOIs	https://doi.org/10.1007/978-1-59745-447-6_7
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-1-59745-447-6_7

Cite this

@article{45bd0360835811df928f000ea68e967b,

title = "YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation",

abstract = "YKL-40, a member of 'mammalian chitinase-like proteins', is secreted by macrophages, neutrophils, chondrocytes, endothelial-, vascular smooth muscle-, and cancer cells. High serum YKL-40 is a biomarker of poor prognosis in patients with cancer, inflammation and increased tissue remodelling. High YKL-40 protein expression assessed by immunohistochemistry is found in breast carcinomas associated with short disease-free survival and in glioblastomas with increased resistance to radiotherapy and decreased overall survival. In this chapter we describe the methods for the detection of (1) YKL-40 protein expression in human tissues (using immunohistochemistry) and cell cultures (using immunocytochemistry); (2) YKL-40 mRNA expression in human tissues (using in situ hybridization and Polymerase Chain Reaction); and (3) YKL-40 protein concentrations in serum or plasma (using Enzyme-Linked ImmunoSorbent Assay).",

author = "Anne Roslind and Johansen, {Julia S}",

note = "Keywords: Animals; Autoantigens; Biological Markers; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Enzyme-Linked Immunosorbent Assay; Female; Glycoproteins; Growth Substances; Humans; Immunohistochemistry; In Situ Hybridization; Inflammation; Lectins; Polymerase Chain Reaction; Tissue Distribution",

year = "2009",

doi = "10.1007/978-1-59745-447-6_7",

language = "English",

volume = "511",

pages = "159--84",

journal = "Methods in Molecular Biology",

issn = "1064-3745",

publisher = "Humana Press",

}

TY - JOUR

T1 - YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation

AU - Roslind, Anne

AU - Johansen, Julia S

N1 - Keywords: Animals; Autoantigens; Biological Markers; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Enzyme-Linked Immunosorbent Assay; Female; Glycoproteins; Growth Substances; Humans; Immunohistochemistry; In Situ Hybridization; Inflammation; Lectins; Polymerase Chain Reaction; Tissue Distribution

PY - 2009

Y1 - 2009

N2 - YKL-40, a member of 'mammalian chitinase-like proteins', is secreted by macrophages, neutrophils, chondrocytes, endothelial-, vascular smooth muscle-, and cancer cells. High serum YKL-40 is a biomarker of poor prognosis in patients with cancer, inflammation and increased tissue remodelling. High YKL-40 protein expression assessed by immunohistochemistry is found in breast carcinomas associated with short disease-free survival and in glioblastomas with increased resistance to radiotherapy and decreased overall survival. In this chapter we describe the methods for the detection of (1) YKL-40 protein expression in human tissues (using immunohistochemistry) and cell cultures (using immunocytochemistry); (2) YKL-40 mRNA expression in human tissues (using in situ hybridization and Polymerase Chain Reaction); and (3) YKL-40 protein concentrations in serum or plasma (using Enzyme-Linked ImmunoSorbent Assay).

AB - YKL-40, a member of 'mammalian chitinase-like proteins', is secreted by macrophages, neutrophils, chondrocytes, endothelial-, vascular smooth muscle-, and cancer cells. High serum YKL-40 is a biomarker of poor prognosis in patients with cancer, inflammation and increased tissue remodelling. High YKL-40 protein expression assessed by immunohistochemistry is found in breast carcinomas associated with short disease-free survival and in glioblastomas with increased resistance to radiotherapy and decreased overall survival. In this chapter we describe the methods for the detection of (1) YKL-40 protein expression in human tissues (using immunohistochemistry) and cell cultures (using immunocytochemistry); (2) YKL-40 mRNA expression in human tissues (using in situ hybridization and Polymerase Chain Reaction); and (3) YKL-40 protein concentrations in serum or plasma (using Enzyme-Linked ImmunoSorbent Assay).

U2 - 10.1007/978-1-59745-447-6_7

DO - 10.1007/978-1-59745-447-6_7

M3 - Journal article

C2 - 19347297

SN - 1064-3745

VL - 511

SP - 159

EP - 184

JO - Methods in Molecular Biology

JF - Methods in Molecular Biology

ER -

YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this